131I-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma

Table 1 Baseline characteristics

Characteristics	Test group (n = 95)	Control group (n = 90)	Statistical analysis
Age (yr)	50.2 (22-80)	51.4 (12-87)	NS
Sex (M/F)	83/12	76/14	NS
Child–Pugh classification			NS
Child class A	91	88
Child class B	4	2
BCLC stage			NS
C	95	90
Size of main tumors
≥ 5 cm	80	81	NS
< 5 cm	15	9	NS
Tumor/liver volume ratio
0%–50%	10	13	NS
≥ 50%	85	77	NS
Hepatitis B/C	70	76	NS
KPS	75.16 ± 7.42	73.89 ± 11.39	NS

BCLC: Barcelona clinic liver cancer; KPS: Karnofsky performance status; NS: Not significant.